We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Vircell Showcases Powerful Automation System and Ready-To-Use Diagnostic Kits at MEDICA 2022

By LabMedica International staff writers
Posted on 13 Nov 2022
Image: VIRCLIA LOTUS is based on VIRCLIA monotest technology to process infectious diseases inmunoassays (Photo courtesy of Vircell)
Image: VIRCLIA LOTUS is based on VIRCLIA monotest technology to process infectious diseases inmunoassays (Photo courtesy of Vircell)

Vircell (Granada, Spain) is participating in this year's edition of MEDICA, the world's largest annual medical technology trade fair, which is taking place from 14-17 November in Düsseldorf, Germany. More than 5,000 exhibitors from 70 countries are presenting their newest products and ideas at MEDICA which draws 120,000 trade visitors from over 170 countries every year.

At MEDICA 2022, Vircell is showcasing its all-in-one CLIA system, VIRCLIA LOTUS which is designed for the automatization of infectious serology with the VirCia Monotest kits. Vircell’s AmpliRun Total Controls are external run controls to monitor the accuracy and precision of the complete analytical process (extraction & amplification). These noninfectious lyophilized run controls include the complete inactivated microorganism in a matrix that mimics human specimens. In combination with the VirClia Monotests, laboratories can daily process a large panel of more than 80 tests with complete traceability. Thanks to the versatility of the VIRCLIA LOTUS fully-automated chemiluminescence solution and wide range of tests for infectious serology, laboratories can process their analysis on a daily basis, without the need to batch samples or refer them to outside centers.

Vircell is also highlighting its VIRPLEX Real Time PCR kits for infectious diseases testing alongside the Aspergillus Galactomannan Ag VIRCLIA Monotest. The test uses sandwich chemiluminescent immunoassay (CLIA) technology for the detection of Aspergillus galactomannan antigen in serum, plasma and human bronchoalveolar lavage (BAL) samples.

Related Links:
Vircell

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System

Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

CAP Updates Cancer Protocols to Refine Breast Cancer Biomarker Reporting and GIST Molecular Testing

Standardized biomarker reporting and molecular profiling are central to pathology-driven cancer care, but evolving practices require laboratories to keep reporting templates current. These templates capture... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more